Abstract
Systemic lupus erythematosus (SLE)—a most common disorder in women of reproductive age—has been described to be associated with adverse pregnancy outcomes. Despite the increased health risks for the mother (preeclampsia, lupus flare, arterial hypertension, gestational diabetes mellitus and thrombotic risk when antiphospholipid antibodies are present) and fetus (miscarriage, stillbirth, premature birth, intrauterine growth restriction and neonatal lupus), the majority of patients can deliver healthy neonates. With appropriate management by a multidisciplinary team, composing rheumatologists, obstetricians and neonatologists, women with SLE can achieve better pregnancy outcomes by monitoring associated predictive indicators, raising major concern for severe complications and somewhat early delivery if necessary. In this review, we summarize the latest advances in secondary infertility and pregnancy-related risk perception for lupus patients, with an emphasis on the safety of biological agents (mainly belimumab and rituximab) and traditional therapeutic regimens.
Similar content being viewed by others
References
IVIG: Current role in bone marrow transplant, malignancy, and immune hematologic disorders (1992) Symposium proceedings. Scottsdale, Arizona, October 10–13, 1990. Semin Hematol 29(3 Suppl 2):1–133
Munroe ME, Vista ES, Merrill JT, Guthridge JM, Roberts VC, James JA (2017) Pathways of impending disease flare in African-American systemic lupus erythematosus patients. J Autoimmun 78:70–78
Ayesha JV, Goswami D (2016) Premature Ovarian Failure: An Association with Autoimmune Diseases. J Clin Diagn Res 10(10):QC10–QC12
Carp HJ, Selmi C, Shoenfeld Y (2012) The autoimmune bases of infertility and pregnancy loss. J Autoimmun 38(2–3):J266-274
Andreoli L, Bertsias GK, Agmon-Levin N, Brown S, Cervera R, Costedoat-Chalumeau N, Doria A, Fischer-Betz R, Forger F, Moraes-Fontes MF et al (2017) EULAR recommendations for women’s health and the management of family planning, assisted reproduction, pregnancy and menopause in patients with systemic lupus erythematosus and/or antiphospholipid syndrome. Ann Rheum Dis 76(3):476–485
Hickman RA, Gordon C (2011) Causes and management of infertility in systemic lupus erythematosus. Rheumatol (Oxf) 50(9):1551–1558
Berkun Y, Zandman-Goddard G, Barzilai O, Boaz M, Sherer Y, Larida B, Blank M, Anaya JM, Shoenfeld Y (2009) Infectious antibodies in systemic lupus erythematosus patients. Lupus 18(13):1129–1135
Khizroeva J, Nalli C, Bitsadze V, Lojacono A, Zatti S, Andreoli L, Tincani A, Shoenfeld Y, Makatsariya A (2019) Infertility in women with systemic autoimmune diseases. Best Pract Res Clin Endocrinol Metab 33(6):101369
Pasoto SG, Mendonca BB, Bonfa E (2002) Menstrual disturbances in patients with systemic lupus erythematosus without alkylating therapy: clinical, hormonal and therapeutic associations. Lupus 11(3):175–180
Luo W, Mao P, Zhang L, Chen X, Yang Z (2020) Assessment of ovarian reserve by serum anti-Mullerian hormone in patients with systemic lupus erythematosus: a meta-analysis. Ann Palliat Med 9(2):207–215
Salmon J, Girardi G, Lockshin M (2007) The antiphospholipid syndrome as a disorder initiated by inflammation: implications for the therapy of pregnant patients. Nature Clin Pract Rheumatol 3(3):140–147
Dooley MA, Nair R (2008) Therapy Insight: preserving fertility in cyclophosphamide-treated patients with rheumatic disease. Nat Clin Pract Rheumatol 4(5):250–257
Vinet E, Pineau C, Gordon C, Clarke AE, Bernatsky S (2008) Systemic lupus erythematosus in women: impact on family size. Arthritis Rheum 59(11):1656–1660
Schmalzing M, Nau LF, Gernert M, Froehlich M, Schwaneck EC, Pecher AC, Saur S, Tony HP, Henes M, Henes J (2020) Sexual function in German women with systemic sclerosis compared to women with systemic lupus erythematosus and evaluation of a screening test. Clin Exp Rheumatol 125(3):59–64
Wagner SJ, Craici I, Reed D, Norby S, Bailey K, Wiste HJ, Wood CM, Moder KG, Liang KP, Liang KV et al (2009) Maternal and foetal outcomes in pregnant patients with active lupus nephritis. Lupus 18(4):342–347
Vagelli R, Tani C, Mosca M (2017) Pregnancy and menopause in patients with systemic lupus erythematosus and/or antiphospholipid syndrome. Practical messages from the EULAR guidelines. Pol Arch Intern Med 127(2):115–121
Buyon JP, Clancy RM, Friedman DM (2009) Autoimmune associated congenital heart block: integration of clinical and research clues in the management of the maternal / foetal dyad at risk. J Intern Med 265(6):653–662
Yazdany J, Trupin L, Kaiser R, Schmajuk G, Gillis JZ, Chakravarty E, Schwarz EB (2011) Contraceptive counseling and use among women with systemic lupus erythematosus: a gap in health care quality? Arthritis Care Res (Hoboken) 63(3):358–365
Culwell KR, Curtis KM, del Carmen CM (2009) Safety of contraceptive method use among women with systemic lupus erythematosus: a systematic review. Obstet Gynecol 114(2 Pt 1):341–353
Gensous N, Doassans-Comby L, Lazaro E, Duffau P (2017) Systemic lupus erythematosus and contraception: a systematic literature review. Rev Med Interne 38(6):358–367
Sanchez-Guerrero J, Uribe AG, Jimenez-Santana L, Mestanza-Peralta M, Lara-Reyes P, Seuc AH, Cravioto MD (2005) A trial of contraceptive methods in women with systemic lupus erythematosus. N Engl J Med 353(24):2539–2549
Petri M, Kim MY, Kalunian KC, Grossman J, Hahn BH, Sammaritano LR, Lockshin M, Merrill JT, Belmont HM, Askanase AD et al (2005) Combined oral contraceptives in women with systemic lupus erythematosus. N Engl J Med 353(24):2550–2558
Jungers P, Dougados M, Pelissier C, Kuttenn F, Tron F, Lesavre P, Bach JF (1982) Influence of oral contraceptive therapy on the activity of systemic lupus erythematosus. Arthritis Rheum 25(6):618–623
Mendel A, Bernatsky S, Pineau CA, St-Pierre Y, Hanly JG, Urowitz MB, Clarke AE, Romero-Diaz J, Gordon C, Bae SC et al (2019) Use of combined hormonal contraceptives among women with systemic lupus erythematosus with and without medical contraindications to oestrogen. Rheumatology 58(7):1259–1267
Tektonidou MG, Andreoli L, Limper M, Amoura Z, Cervera R, Costedoat-Chalumeau N, Cuadrado MJ, Dorner T, Ferrer-Oliveras R, Hambly K et al (2019) EULAR recommendations for the management of antiphospholipid syndrome in adults. Ann Rheum Dis 78(10):1296–1304
Clowse ME, Jamison M, Myers E, James AH (2008) A national study of the complications of lupus in pregnancy. Am J Obstet Gynecol 199(2):127
Dong Y, Yuan F, Dai Z, Wang Z, Zhu Y, Wang B (2020) Preeclampsia in systemic lupus erythematosus pregnancy: a systematic review and meta-analysis. Clin Rheumatol 39(2):319–325
Ugolini-Lopes MR, Torrezan GT, Gandara APR, Olivieri EHR, Nascimento IS, Okazaki E, Bonfa E, Carraro DM, de Andrade DCO (2019) Enhanced type I interferon gene signature in primary antiphospholipid syndrome: association with earlier disease onset and preeclampsia. Autoimmun Rev 18(4):393–398
Moroni G, Doria A, Giglio E, Imbasciati E, Tani C, Zen M, Strigini F, Zaina B, Tincani A, Gatto M et al (2016) Maternal outcome in pregnant women with lupus nephritis. A prospective multicenter study. J Autoimmun 74:194–200
Duley L, Henderson-Smart DJ, Meher S, King JF (2007) Antiplatelet agents for preventing pre-eclampsia and its complications. Cochrane Database Syst Rev 2:CD004659
Clowse ME, Magder LS, Witter F, Petri M (2005) The impact of increased lupus activity on obstetric outcomes. Arthritis Rheum 52(2):514–521
Petri M (1997) Hopkins lupus pregnancy center: 1987 to 1996. Rheum Dis Clin North Am 23(1):1–13
Clark CA, Spitzer KA, Nadler JN, Laskin CA (2003) Preterm deliveries in women with systemic lupus erythematosus. J Rheumatol 30(10):2127–2132
Yasmeen S, Wilkins EE, Field NT, Sheikh RA, Gilbert WM (2001) Pregnancy outcomes in women with systemic lupus erythematosus. J Matern Fetal Med 10(2):91–96
Johnson MJ, Petri M, Witter FR, Repke JT (1995) Evaluation of preterm delivery in a systemic lupus erythematosus pregnancy clinic. Obstet Gynecol 86(3):396–399
Cortes-Hernandez J, Ordi-Ros J, Paredes F, Casellas M, Castillo F, Vilardell-Tarres M (2002) Clinical predictors of fetal and maternal outcome in systemic lupus erythematosus: a prospective study of 103 pregnancies. Rheumatol (Oxf) 41(6):643–650
Ozmen A, Unek G, Korgun ET (2017) Effect of glucocorticoids on mechanisms of placental angiogenesis. Placenta 52:41–48
Ignacchiti LM, Costa RB, de Ramires JG, Dos Cunha SF, de Ramires JN, Levy R, Mendes KE (2021) The association between active proliferative lupus nephritis during pregnancy and small for gestational age newborns. Clin Exp Rheumatol 39(5):1043–1048
De Carolis S, Botta A, Santucci S, Salvi S, Moresi S, Di Pasquo E, Del Sordo G, Martino C (2012) Complementemia and obstetric outcome in pregnancy with antiphospholipid syndrome. Lupus 21(7):776–778
Petri M, Howard D, Repke J, Goldman DW (1992) The Hopkins Lupus Pregnancy Center: 1987–1991 update. Am J Reprod Immunol 28(3–4):188–191
Lee LA, Frank MB, McCubbin VR, Reichlin M (1994) Autoantibodies of neonatal lupus erythematosus. J Invest Dermatol 102(6):963–966
Izmirly PM, Saxena A, Kim MY, Wang D, Sahl SK, Llanos C, Friedman D, Buyon JP (2011) Maternal and fetal factors associated with mortality and morbidity in a multi-racial/ethnic registry of anti-SSA/Ro-associated cardiac neonatal lupus. Circulation 124(18):1927–1935
Cimaz R, Spence DL, Hornberger L, Silverman ED (2003) Incidence and spectrum of neonatal lupus erythematosus: a prospective study of infants born to mothers with anti-Ro autoantibodies. J Pediatr 142(6):678–683
Askanase AD, Friedman DM, Copel J, Dische MR, Dubin A, Starc TJ, Katholi MC, Buyon JP (2002) Spectrum and progression of conduction abnormalities in infants born to mothers with anti-SSA/Ro-SSB/La antibodies. Lupus 11(3):145–151
Knight CL, Nelson-Piercy C (2017) Management of systemic lupus erythematosus during pregnancy: challenges and solutions. Open Access Rheumatol 9:37–53
Keriakos R, Bhatta SR, Morris F, Mason S, Buckley S (2011) Pelvic girdle pain during pregnancy and puerperium. J Obstet Gynaecol 31(7):572–580
Gianfreda D, Quaglini S, Frontini G, Raffiotta F, Messa P, Moroni G (2017) Does pregnancy have any impact on long term damage accrual and on the outcome of lupus nephritis? J Autoimmun 84:46–54
Barbhaiya M, Bermas BL (2013) Evaluation and management of systemic lupus erythematosus and rheumatoid arthritis during pregnancy. Clin Immunol 149(2):225–235
Ko HS, Ahn HY, Jang DG, Choi SK, Park YG, Park IY, Lee G, Park SH, Shin JC (2011) Pregnancy outcomes and appropriate timing of pregnancy in 183 pregnancies in Korean patients with SLE. Int J Med Sci 8(7):577–583
Imbasciati E, Tincani A, Gregorini G, Doria A, Moroni G, Cabiddu G, Marcelli D (2009) Pregnancy in women with pre-existing lupus nephritis: predictors of fetal and maternal outcome. Nephrol Dial Transplant 24(2):519–525
Moroni G, Ponticelli C (2005) Pregnancy after lupus nephritis. Lupus 14(1):89–94
Yelnik CM, Laskin CA, Porter TF, Branch DW, Buyon JP, Guerra MM, Lockshin MD, Petri M, Merrill JT, Sammaritano LR et al (2016) Lupus anticoagulant is the main predictor of adverse pregnancy outcomes in aPL-positive patients: validation of PROMISSE study results. Lupus Sci Med 3(1):e000131
Motta M, Tincani A, Faden D, Zinzini E, Lojacono A, Marchesi A, Frassi M, Biasini C, Zatti S, Chirico G (2005) Follow-up of infants exposed to hydroxychloroquine given to mothers during pregnancy and lactation. J Perinatol 25(2):86–89
Park-Wyllie L, Mazzotta P, Pastuszak A, Moretti ME, Beique L, Hunnisett L, Friesen MH, Jacobson S, Kasapinovic S, Chang D et al (2000) Birth defects after maternal exposure to corticosteroids: prospective cohort study and meta-analysis of epidemiological studies. Teratology 62(6):385–392
Sammaritano LR, Bermas BL (2014) The medical management of the rheumatology patient during pregnancy. Springer, New York
Gotestam Skorpen C, Hoeltzenbein M, Tincani A, Fischer-Betz R, Elefant E, Chambers C, da Silva J, Nelson-Piercy C, Cetin I, Costedoat-Chalumeau N et al (2016) The EULAR points to consider for use of antirheumatic drugs before pregnancy, and during pregnancy and lactation. Ann Rheum Dis 75(5):795–810
Hall JG, Pauli RM, Wilson KM (1980) Maternal and fetal sequelae of anticoagulation during pregnancy. Am J Med 68(1):122–140
Galambosi PJ, Kaaja RJ, Stefanovic V, Ulander VM (2012) Safety of low-molecular-weight heparin during pregnancy: a retrospective controlled cohort study. Eur J Obstet Gynecol Reprod Biol 163(2):154–159
Clowse ME, Magder L, Witter F, Petri M (2006) Hydroxychloroquine in lupus pregnancy. Arthritis Rheum 54(11):3640–3647
ACOG Practice Bulletin No (2011) 118: antiphospholipid syndrome. Obstet Gynecol 117(1):192–199
Limper M, Scire CA, Talarico R, Amoura Z, Avcin T, Basile M, Burmester G, Carli L, Cervera R, Costedoat-Chalumeau N et al (2018) Antiphospholipid syndrome: state of the art on clinical practice guidelines. RMD Open 4(Suppl 1):e000785
Tunks RD, Clowse ME, Miller SG, Brancazio LR, Barker PC (2013) Maternal autoantibody levels in congenital heart block and potential prophylaxis with antiinflammatory agents. Am J Obstet Gynecol 208(1):64–67
Alstead EM, Ritchie JK, Lennard-Jones JE, Farthing MJ, Clark ML (1990) Safety of azathioprine in pregnancy in inflammatory bowel disease. Gastroenterology 99(2):443–446
Bramham K, Chusney G, Lee J, Lightstone L, Nelson-Piercy C (2013) Breastfeeding and tacrolimus: serial monitoring in breast-fed and bottle-fed infants. Clin J Am Soc Nephrol 8(4):563–567
Bar Oz B, Hackman R, Einarson T, Koren G (2001) Pregnancy outcome after cyclosporine therapy during pregnancy: a meta-analysis. Transplantation 71(8):1051–1055
Parke A (1992) The role of IVIG in the management of patients with antiphospholipid antibodies and recurrent pregnancy losses. Clin Rev Allergy 10(1–2):105–118
Bag-Ozbek A, Hui-Yuen JS (2021) Emerging B-Cell Therapies in Systemic Lupus Erythematosus. Ther Clin Risk Manag 17:39–54
Auyeung-Kim DJ, Devalaraja MN, Migone TS, Cai W, Chellman GJ (2009) Developmental and peri-postnatal study in cynomolgus monkeys with belimumab, a monoclonal antibody directed against B-lymphocyte stimulator. Reprod Toxicol 28(4):443–455
Wasserman S, Clowse MEB (2014) Systemic lupus erthematosus. In: Sammaritano LR, Bermas BL (eds) Contraception and pregnancy in patients with rheumatic disease. Springer, New York, pp 79–97
Palmeira P, Quinello C, Silveira-Lessa AL, Zago CA, Carneiro-Sampaio M (2012) IgG placental transfer in healthy and pathological pregnancies. Clin Dev Immunol 2012:985646
Friedrichs B, Tiemann M, Salwender H, Verpoort K, Wenger MK, Schmitz N (2006) The effects of rituximab treatment during pregnancy on a neonate. Haematologica 91(10):1426–1427
Funding
The authors declare that no funds, grants, or other support were received during the preparation of this manuscript.
Author information
Authors and Affiliations
Contributions
SZ: Manuscript writing, Providing the idea for the article, Literature search and management. XH: Literature search. WL: Literature search. QW: Literature search. JW: Manuscript editing, Project development. All authors contributed to the study conception. The first draft of the manuscript was written by SZ and all authors commented on previous versions of the manuscript. All authors read and approved the final manuscript.
Corresponding author
Additional information
Publisher's Note
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.
Rights and permissions
Springer Nature or its licensor holds exclusive rights to this article under a publishing agreement with the author(s) or other rightsholder(s); author self-archiving of the accepted manuscript version of this article is solely governed by the terms of such publishing agreement and applicable law.
About this article
Cite this article
Zhang, S., Han, X., Liu, W. et al. Pregnancy in patients with systemic lupus erythematosus: a systematic review. Arch Gynecol Obstet 308, 63–71 (2023). https://doi.org/10.1007/s00404-022-06718-7
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s00404-022-06718-7